Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Mitral stenosis Stories

2014-04-16 08:32:01

Funding Will Enable Initiation of Blinded, Randomized Clinical Trial and Expanded Commercialization of CARILLON® Mitral Contour System® KIRKLAND, Wash., April 16, 2014 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced the completion of a $20 million financing. M. H. Carnegie & Co. and Lumira Capital led the financing as part of an international syndicate of institutional investors from Australia, the U.S. and Canada. The financing follows the company's completion...

2014-01-30 12:28:23

DETROIT, Jan. 30, 2014 /PRNewswire/ -- For the first time in the U.S., doctors at Henry Ford Hospital have used an artificial heart valve designed for aortic valve replacement to repair a mitral valve that was narrowed with calcium buildup. And they did it all through a catheter. (Photo: http://photos.prnewswire.com/prnh/20140130/DE56074 ) Approximately 5 million people in the U.S. are diagnosed with heart valve disease each year. With an aging population that is often too frail...

2013-10-30 20:24:51

Results Show Treatment Provides Clinical Benefits and Improves Quality of Life for Patients with Debilitating Mitral Valve Disease Who Are at Prohibitive Surgical Risk ABBOTT PARK, Ill., Oct. 30, 2013 /PRNewswire/ -- Abbott today announced clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure, and functional improvements for patients treated with the company's first-in-class, catheter-based MitraClip(®) therapy for patients with degenerative...

2012-07-10 10:25:30

WEST BRIDGEWATER, Mass., July 10, 2012 /PRNewswire/ -- Cardiosolutions, Inc. an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation, today announced it has received a minority investment from Sorin Group (Reuters Code: SORN.MI), a global medical device company and an international leader in the treatment of cardiovascular disease. Cardiosolutions' technology consists of a proprietary catheter...

2012-06-04 02:25:14

MISGAV, Israel, June 4, 2012 /PRNewswire/ -- MitrAssist Medical Ltd., a developer of minimally invasive products for treating heart disease, announced today that it received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses. Today's standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open heart surgery. MitrAssist's unique design preserves the ventricular dynamic mode of...

2012-05-21 06:24:38

KIRKLAND, Wash., May 21, 2012 /PRNewswire/ -- Cardiac Dimensions®,( )Inc. today announced that data from its landmark TITAN clinical trial has been published in the most recent issue of the European Journal of Heart Failure. Titled "Treatment of Functional Mitral Regurgitation by Percutaneous Annuloplasty: Results of the TITAN Trial," the manuscript features two-year follow-up data on patients implanted with the CARILLON® Mitral Contour System® as well as one-year...

2012-04-19 12:31:46

Leading Middle East cardiologists call for adoption of rheumatic heart disease screening and prevention programs at the World Congress of Cardiology Patients with rheumatic heart disease (RHD) are being admitted to hospital too late to prevent the need for heart surgery, according to a new study carried out by doctors in Yemen and presented today at the World Congress of Cardiology. RHD is a devastating consequence of repeated episodes of rheumatic fever. The disease progresses over...

2012-04-10 13:49:15

TAVI improves heart function and exercise capacity German researchers report success with transcatheter aortic valve implantation (TAVI) in patients with low-flow, low-gradient aortic stenosis–a special form of aortic stenosis that is difficult to treat. Results published in the April issue of Catheterization and Cardiovascular Interventions, the peer-reviewed journal of the Society for Cardiovascular Angiography and Interventions (SCAI), show that while all-cause mortality was high...

2012-04-10 12:24:34

TAVI Improves Heart Function and Exercise Capacity German researchers report success with transcatheter aortic valve implantation (TAVI) in patients with low-flow, low-gradient aortic stenosis–a special form of aortic stenosis that is difficult to treat. Results published in the April issue of Catheterization and Cardiovascular Interventions, the peer-reviewed journal of the Society for Cardiovascular Angiography and Interventions (SCAI), show that while all-cause mortality was high...

2011-11-07 17:32:00

KIRKLAND, Wash., Nov. 7, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that an update to its landmark TITAN clinical trial will be given as part of the 23rd annual Transcathether Cardiovascular Therapeutics (TCT) Conference being held at the Moscone Center in San Francisco. Steven L. Goldberg, M.D., the Company's Chief Clinical Officer will deliver a presentation entitled, Cardiac Dimensions CARILLON XE2: Foundational Results and Design Iteration Toward...